CD19 and non-Hodgkin lymphoma: As such, the CD19 CAR T products would be the first to obtain regulatory approval for B-cell acute lymphoblastic leukemia (B-ALL) in patients up to age 25 and in certain B-cell non-Hodgkin’s lymphomas (NHL).